COVID-19 - Evaluation von Biomarkern im klinischen Verlauf der Erkrankung / vorgelegt von Anke Hillebrecht ; Referentin: Prof. Dr. med. S. Blaschke-Steinbrecher, Ko-Referent/in: Prof. Dr. med. U. Groß

The course of serological and laboratory biomarkers during the phase of inpatient treatment of COVID-19 patients was investigated. Data from a total of n=47 patients were retrospectively analyzed. These included selected vital signs, laboratory parameters, and serial RT-qPCR and antibody diagnostics in addition to age and sex. Higher respiratory rates were highly significantly (p....

The course of serological and laboratory biomarkers during the phase of inpatient treatment of COVID-19 patients was investigated. Data from a total of n=47 patients were retrospectively analyzed. These included selected vital signs, laboratory parameters, and serial RT-qPCR and antibody diagnostics in addition to age and sex.Higher respiratory rates were highly significantly (p<0.001) associated with higher COVID-19 disease severity. The same was true for the presence of dyspnea (p<0.001) and the CRB-65 score obtained in the emergency department (p<0.001). A significant association (p=0.05) was shown for the presence of fever with higher COVID-19 disease severity scores.In laboratory diagnostics, highly significant differences were found between COVID-19 disease severity and the level of leukocyte and lymphocyte counts (p<0.007) as well as plasma concentrations of CRP (p<0.001), PCT (p<0.001), LDH (p<0.001) and D-dimer (p<0.02).Negative SARS-CoV-2 PCR tests were obtained significantly later in patients with higher COVID-19 disease severity than in patients with milder courses. The peak of both SARS-CoV-2 IgG and SARS-CoV-2 IgA antibodies was found to occur around day 20 after symptom onset. Time points of SARS-CoV-2 IgG and IgA seroconversion were found to be significantly associated with BMI class (p<0.001).By assessment of clinical disease severity and laboratory as well as virological bio-markers risk groups of COVID-19 patients could be identified in the ED thus helping to adjust risk-adapted treatment strategies.$yLinzenz.

Medienart:	E-Book

Erscheinungsjahr:	2022
Erschienen:	Göttingen: 2022

Weitere Ausgaben:	Erscheint auch als Druck-Ausgabe: COVID-19 - Evaluation von Biomarkern im klinischen Verlauf der Erkrankung

Sprache:	Deutsch

Beteiligte Personen:	Hillebrecht, Anke [VerfasserIn] Blaschke-Steinbrecher, Sabine [Akademische/r BetreuerIn] Groß, Uwe [Akademische/r BetreuerIn]
Hochschulschrift:	Dissertation, Georg-August-Universität Göttingen, 2022

Links:	Volltext [kostenfrei] Volltext [kostenfrei] d-nb.info [kostenfrei]

Themen:	Hochschulschrift

Umfang:	1 Online-Resource ; Illustrationen, Diagramme

Weitere IDs:	urn:nbn:de:gbv:7-ediss-13945-6

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	1797016709